HemaSphere (Jun 2022)
P1172: DUVELISIB IN PATIENTS WITH RELAPSED/REFRACTORY PERIPHERAL T-CELL LYMPHOMA FROM THE PHASE 2 PRIMO TRIAL: UPDATED EXPANSION PHASE ANALYSIS
- P. L. Zinzani, MD, PhD,
- J. Zain, MD,
- M. Mead, BS, MD,
- C. Casulo, MD,
- E. D. Jacobsen, MD,
- G. Gritti, MD, PhD,
- L. Pinter-Brown, MD,
- K. Isutzu, MD,
- D. Cohan, MD,
- M. Daugherty, PharmD,
- J. E. Brammer, MD,
- N. Mehta-Shah, MD,
- B. Pro, MD,
- S. M. Horwitz, MD
Affiliations
- P. L. Zinzani, MD, PhD
- J. Zain, MD
- 1 Institute of Hematology “Seràgnoli”, University of Bologna, Bologna, Italy
- M. Mead, BS, MD
- C. Casulo, MD
- 3 Department of Medicine, Division of Hematology/Oncology, UCLA Medical Center, Santa Monica
- E. D. Jacobsen, MD
- 4 University of Rochester Medical Center, James P. Wilmot Cancer Center, Rochester
- G. Gritti, MD, PhD
- 5 Dana-Farber Cancer Institute, Boston, United States of America
- L. Pinter-Brown, MD
- 6 Hematology and Bone Marrow Transplant Unit, Ospedale Papa Giovanni XXIII, Bergamo, Italy
- K. Isutzu, MD
- 7 University of California-Irvine, Irvine, United States of America
- D. Cohan, MD
- 8 National Cancer Center Hospital, Tokyo, Japan
- M. Daugherty, PharmD
- 9 Secura Bio, Inc.
- J. E. Brammer, MD
- 10 SecuraBio, Inc, Las Vegas
- N. Mehta-Shah, MD
- 11 Division of Hematology, Department of Internal Medicine, The Ohio State University, Columbus
- B. Pro, MD
- 12 Washington University School of Medicine in St. Louis, Saint Louis
- S. M. Horwitz, MD
- 13 Columbia University Herbert Irving Comprehensive Cancer Center
- DOI
- https://doi.org/10.1097/01.HS9.0000847552.42271.7c
- Journal volume & issue
-
Vol. 6
pp. 1058 – 1059
Abstract
No abstracts available.